Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
AG Medical Company, Saint Aubin, France.
Radiat Environ Biophys. 2020 Aug;59(3):553-558. doi: 10.1007/s00411-020-00849-8. Epub 2020 May 24.
COTI (collar therapy indicator) has been recently introduced for the detection of gamma rays with emphasis on thyroid investigations. The aim of this study was to test the feasibility of a prototype version of COTI including activity detectors with low sensitivity in performing thyroid uptake measurements for a large group of patients. Consequently, thyroid uptake tests were carried out for a total of 89 patients (22 males and 67 females; age: 44 ± 13 years) with thyroid cancer (n = 74), hyperthyroidism (n = 16) at 2 and 24 h after administration of 0.44-2 MBq of I. Eight individuals among the thyroid cancer patients were monitored up to 96 h after administration. The COTI device was equipped with two CsI (Tl) detectors, known as LoHi type, sensitive to activity ranges from 0.02 to 30 MBq of I. The uptake values from COTI were compared with those measured with a standard probe. It was found that the mean uptake of thyroid activity in thyroid cancer patients was 2.1 ± 1.3% at 2 h when measured with the standard probe, while it was 2.2 ± 1.2% when measured with COTI. In addition, the average uptake at 24 h after administration was 2.5 ± 3.2% and 3.2 ± 3.8% measured with COTI and the standard probe, respectively. A strong correlation was found at 24 h between the results obtained with COTI and the standard probe, while a weaker correlation was seen at 2 h. Overall, there was no significant difference between the results obtained with the standard probe and those obtained with COTI at both 2 and 24 h (P ≥ 0.05). Besides, 85% of the uptake values measured with COTI were less than those measured with the standard probe at the 24 h after administration. The average uptake value was 0.9 ± 0.8% after 96 h by COTI, and 1.4 ± 1.3% by the standard probe. Pertaining to the hyperthyroidism patients, COTI showed mean uptake values of 20 ± 16% and 23 ± 18% at 2 and 24 h, respectively. In contrast, the standard probe suggested higher mean uptake values of 26 ± 18% and 30 ± 22%, respectively. It is concluded that the prototype of COTI used in the present study has been proved to be a feasible and promising tool in thyroid investigations. It is noted, however, that the next COTI generation should include detectors equipped with collimator and energy discrimination.
COTI(领圈治疗指示剂)最近被引入用于检测伽马射线,重点是甲状腺研究。本研究的目的是测试包括低灵敏度活性探测器的 COTI 原型版本在对一大群患者进行甲状腺摄取测量时的可行性。因此,对 89 名患者(22 名男性和 67 名女性;年龄:44±13 岁)进行了甲状腺摄取测试,这些患者患有甲状腺癌(n=74)、甲状腺功能亢进(n=16),在给药后 2 和 24 小时进行了 I 摄取测试。在给药后 96 小时监测了甲状腺癌患者中的 8 人。COTI 设备配备了两个 CsI(Tl)探测器,称为 LoHi 型,对 0.02 到 30MBq 的 I 活性范围敏感。使用标准探头测量时,甲状腺癌患者的甲状腺活动摄取值在 2 小时时为 2.1±1.3%,而使用 COTI 测量时为 2.2±1.2%。此外,给药后 24 小时的平均摄取量分别为 2.5±3.2%和 3.2±3.8%,使用 COTI 和标准探头测量。在 24 小时时,使用 COTI 和标准探头获得的结果之间发现了很强的相关性,而在 2 小时时则发现了较弱的相关性。总体而言,在 2 和 24 小时时,使用标准探头和 COTI 获得的结果之间没有显著差异(P≥0.05)。此外,在给药后 24 小时,使用 COTI 测量的摄取值中有 85%小于使用标准探头测量的摄取值。COTI 的平均摄取值在给药后 96 小时为 0.9±0.8%,而标准探头为 1.4±1.3%。对于甲状腺功能亢进症患者,COTI 在 2 小时和 24 小时时的平均摄取值分别为 20±16%和 23±18%。相比之下,标准探头提示的平均摄取值分别为 26±18%和 30±22%。综上所述,本研究中使用的 COTI 原型已被证明是一种可行且有前途的甲状腺研究工具。然而,需要注意的是,下一代 COTI 应该包括配备准直器和能量甄别器的探测器。